杜云云, 李庆敏. T-细胞幼淋巴细胞白血病治疗的研究进展[J]. 中国肿瘤临床, 2017, 44(21): 1108-1111. DOI: 10.3969/j.issn.1000-8179.2017.21.610
引用本文: 杜云云, 李庆敏. T-细胞幼淋巴细胞白血病治疗的研究进展[J]. 中国肿瘤临床, 2017, 44(21): 1108-1111. DOI: 10.3969/j.issn.1000-8179.2017.21.610
DU Yunyun, LI Qingmin. Research progress on the therapy of T-cell prolymphocytic leukemia[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 44(21): 1108-1111. DOI: 10.3969/j.issn.1000-8179.2017.21.610
Citation: DU Yunyun, LI Qingmin. Research progress on the therapy of T-cell prolymphocytic leukemia[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 44(21): 1108-1111. DOI: 10.3969/j.issn.1000-8179.2017.21.610

T-细胞幼淋巴细胞白血病治疗的研究进展

Research progress on the therapy of T-cell prolymphocytic leukemia

  • 摘要: 幼淋巴细胞白血病(prolymphocytic leukemia,PLL)是一种罕见但恶性程度极高的成熟淋巴肿瘤,其中T-细胞幼淋巴细胞白血病(T-cell prolymphocytic leukemia,T-PLL)这种亚型被认为难以治愈,临床治疗目的主要是提高治疗有效率和延长缓解期。随着对白血病发生发展机制研究的不断深入,目前T-PLL的治疗手段取得了较大的进步,其中表观遗传学的干预治疗为治愈TPLL提供了新的研究方向,本文就T-PLL的治疗研究进展进行综述。

     

    Abstract: Prolymphocytic leukemia is a rare disease with typical characteristics, including aggressive progression and high mortality rate, and T-cell prolymphocytic leukemia (T-PLL) is regarded as an intractable subtype. Current therapeutic approaches mainly aim to improve their efficacy and remission against this disease. This paper presents a review about the research progress on T-PLL therapies. With remarkable research progress on leukemia pathogenesis, therapies for T-PLL have been greatly enhanced. Among treatment strategies, epigenetic therapy shows potential for clinical applications.

     

/

返回文章
返回